Meloxicam Discontinuation Before Surgery
Stop meloxicam 4 days before surgery to minimize perioperative bleeding risk. This recommendation is based on the drug's elimination half-life and the need to allow adequate clearance before surgical procedures.
Rationale and Evidence
Meloxicam is a long-acting NSAID with an elimination half-life of approximately 15-20 hours. The standard approach for NSAID discontinuation requires stopping the medication for five elimination half-lives to ensure adequate drug clearance and restoration of normal platelet function 1.
Specific Timing Guidelines
- Meloxicam (Mobic): Discontinue 4 days preoperatively 2
- This timing allows for approximately 4-5 half-lives to elapse, reducing residual antiplatelet effects to minimal levels
Context Within NSAID Management
The perioperative management of NSAIDs varies significantly based on the specific agent's pharmacokinetics 1:
Short-acting NSAIDs (stop 1-2 days before):
- Ibuprofen, diclofenac, ketorolac
Intermediate-acting NSAIDs (stop 2-4 days before):
- Etodolac, indomethacin, meloxicam, naproxen
Long-acting NSAIDs (stop 6-10 days before):
- Oxaprozin, piroxicam
Important Clinical Considerations
Bleeding Risk Assessment
The decision to discontinue meloxicam should account for:
- Type of surgery: High bleeding-risk procedures (neurosurgery, spinal surgery, major cancer operations) warrant strict adherence to the 4-day discontinuation window 2
- Combination therapy: NSAIDs combined with anticoagulants or antiplatelet agents increase bleeding risk 3-6 fold 1
Common Pitfalls to Avoid
Don't confuse meloxicam with short-acting NSAIDs: Unlike ibuprofen (2-day discontinuation), meloxicam requires the full 4-day window due to its longer half-life
Don't restart too early postoperatively: For high bleeding-risk surgeries, delay resumption until adequate hemostasis is achieved (typically 48-72 hours post-procedure)
Monitor for hidden NSAID use: Patients may be taking over-the-counter NSAIDs without reporting them; specifically ask about all pain medications
Special Populations
Renal impairment: Consider extending the discontinuation period beyond 4 days, as meloxicam clearance is reduced in patients with decreased renal function 1
Hepatic impairment: Use caution and potentially extend the preoperative discontinuation window 1
Postoperative Resumption
Resume meloxicam based on surgical bleeding risk:
- Low-to-moderate bleeding risk: May resume 24 hours postoperatively once hemostasis is confirmed
- High bleeding risk (spine surgery, intracranial procedures): Wait 48-72 hours before resuming 2
The 4-day preoperative discontinuation provides an appropriate balance between minimizing bleeding complications while not unnecessarily prolonging the period without anti-inflammatory analgesia.